Skip to main content

Site notifications

CIPLA TEDUGLUTIDE, REVACIP Cipla Australia Pty Ltd

Product name
CIPLA TEDUGLUTIDE, REVACIP
Accepted date
Mar-2025
Active ingredients
teduglutide
Proposed indication
Cipla Teguglutide is used to treat adults and children (2 years and older) with short bowel syndrome who need parenteral nutrition (when nutrients are infused directly into the bloodstream). Patients should be stable on their parenteral support for at least 4 weeks before starting teduglutide therapy.
Application type
A (new medicine)
Publication date
Mar-2025